Weight-loss GLP-1 Injections Could Halve Sick Leave, NHS Hopes Rise
Weight-loss GLP-1 Injections Could Halve Sick Leave, NHS Hopes Rise
A study suggests GLP-1 weight-loss injections could cut sickness absence by up to 50%, easing NHS pressures.
London — A recent UK study suggests GLP-1 weight-loss injections could halve sickness absence among patients over a nine-month period, a finding that would ease NHS pressure and boost productivity in the wider workforce. Researchers observed that days off work due to illness dropped by about half for those prescribed GLP-1 therapies, pointing to meaningful improvements in workforce health if verified in broader analyses.
If confirmed, the results could influence how obesity treatment is prioritised within primary care and occupational health programs, and might shift employer expectations about sickness absence and disability leave. The potential for reduced time off work would also align with broader public health goals to tackle obesity and its ripple effects on productivity and healthcare demand.
Experts caution that not all patients respond the same way, and long-term safety, cost, and accessibility will determine whether these benefits translate to real-world settings. Adherence to injections, monitoring for side effects such as gastrointestinal symptoms, and ensuring equitable access across populations will be crucial as data from additional trials emerge. While promising, policymakers stress that this is one piece of a larger puzzle around obesity, prevention, and lifestyle support, requiring more robust data before widespread adoption.
